Clinical Trials | 07/09/2022 | By Sudeep Soparkar | 129
3D model created for rare neuromuscular disorder
Scientists have created a bioengineered 3-D model that mimics the biology of two rare diseases. The researchers used the 'tissue chip' model to show how a drug could potentially treat the diseases, providing data for a drug company's FDA submission for authorization for clinical testing.
Clinical Trials | 04/05/2022 | By Sudeep Soparkar | 196
New patent grant to OSE Immunotherapeutics by EPO
OSE Immunotherapeutics receives European patent covering novel myeloid immune checkpoint target, CLEC-1 for cancer treatment
Clinical Trials | 03/05/2022 | By Sudeep Soparkar | 133
EMA reviews gene therapy for Haemophilia B
EMA (European Medicines Agency) has started reviewing the CSL Behring's MAA for gene therapy etranacogene dezaparvovec (EtranaDez), for the patients getting treatment for Haemophila B.
Clinical Trials | 28/04/2022 | By Sudeep Soparkar | 178
ALS drug by Biogen and Ionis Pharmaceuticals fails in trials
Biogen and Ionis Pharmaceuticals were hoping to be the first to find a cure for ALS. That dream has now fizzled out with the companies calling it quits after receiving disappointing results from a phase 1 clinical trial.
Clinical Trials | 27/04/2022 | By Sudeep Soparkar | 129
Anti-Tigit drug of Roche fails stage study
Roche's Genentech had disappointing news to share this week regarding its lung cancer hopeful.
Clinical Trials | 26/04/2022 | By Sudeep Soparkar | 126
Funds of $130m raised for B cell medications
Be Bio raises $130m to foster designed B cell medications. As a feature of the financing, ARCH Venture Partners overseeing chief Steven Gillis will join Be Bio's governing body.
Clinical Trials | 23/04/2022 | By Sudeep Soparkar | 115
BioXcel to develop drugs in oncology
BioXcel shapes entirely claimed auxiliary OnkosXcel to foster prescriptions centered in oncology
Clinical Trials | 21/04/2022 | By Sudeep Soparkar | 120
IDB therapies to improve with lymphoid cell maturity
New knowledge on lymphoid cell maturity could lead to more effective IBD therapies
Clinical Trials | 18/04/2022 | By Sudeep Soparkar | 205
Effects of rilzabrutinib in individuals with insusceptible thrombocytopenia
Positive phase 1/2 study results of rilzabrutinib in people with immune thrombocytopenia published in The New England Journal of Medicine
Clinical Trials | 16/04/2022 | By Sudeep Soparkar | 188
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy